(XERS) Xeris Pharmaceuticals - Ratings and Ratios

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a biopharmaceutical company headquartered in Chicago, Illinois, specializes in developing and commercializing therapies for rare and acute medical conditions. The companys product portfolio includes Gvoke, a ready-to-use liquid-stable glucagon for treating severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor approved for endogenous hypercortisolemia in adult patients with Cushings syndrome. Xeris is also advancing its pipeline with XP-8121, a once-weekly subcutaneous levothyroxine injection in Phase I clinical trials for hypothyroidism, and non-aqueous XeriSol and XeriJect technologies for various therapies. Incorporated in 2005, the company focuses on addressing unmet medical needs through innovative drug delivery systems.

From a technical perspective, XERS has shown volatility, with an ATR of 0.17, indicating moderate price fluctuations. The stock is currently trading at $3.76, above its 20-day SMA of $3.69 but below its 50-day SMA of $3.51. The 200-day SMA of $2.89 suggests a potential long-term upward trend. Fundamental analysis highlights a market cap of $535.20M, a P/B ratio of 3.34, and a P/S ratio of 2.86, reflecting moderate valuation. The RoE of 222.83% indicates strong profitability relative to equity.